Mark Woodward
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark Woodward has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Rachel R. Huxley
The George Institute for Global Health, University of New South Wales, Sydney, Australia
4 shared publications - Tai Hing Lam
The University of Hong Kong
3 shared publications - Adrienne Kirby
NHMRC Clinical Trials Centre at The University of Sydney, The University of Sydney, Sydney, New South Wales, 2006, Australia
2 shared publications - Alexandra Martiniuk
University of Sydney, Faculty of Medicine and Health, School of Public Health, Sydney, New South Wales, Australia; University of Toronto, Toronto, Ontario, Canada
2 shared publications Andrew M. Tonkin
Monash University, Melbourne, Victoria, Australia
2 shared publicationsAnushka Patel
The George Institute for International Health, University of Sydney
2 shared publications
Latest Publications
- Open Access
- 11 July 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (13)
Changes in plasma lipids predict pravastatin efficacy in secondary prevention
BACKGROUND: Statins have pleiotropic effects on lipid metabolism. The relationship between these effects and future cardiovascular events is unknown. We characterized the changes in lipids upon pravastatin treatment and defined the relationship with risk reduction for future cardiovascular events. METHODS: Plasma lipids ( n = 342) were measured in baseline and 1-year follow-up samples from a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study subcohort ( n = 4991). The associations of changes in lipids with treatment and cardiovascular outcomes were investigated using linear and Cox regression. The effect of treatment on future cardiovascular outcomes was examined by the relative risk reduction (RRR). RESULTS: Pravastatin treatment was associated with changes in 206 lipids. Species containing arachidonic acid were positively associated while phosphatidylinositol species were negatively associated with pravastatin treatment. The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C) and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4). Change in PI(36:2)/PC(38:4) mediated 58% of the treatment effect. Stratification of patients into quartiles of change in PI(36:2)/PC(38:4) indicated no benefit of pravastatin in the fourth quartile. CONCLUSION: The change in PI(36:2)/PC(38:4) predicted benefit from pravastatin, independent of change in LDL-C, demonstrating its potential as a biomarker for monitoring the clinical benefit of statin treatment in secondary prevention. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry identifier ACTRN12616000535471. FUNDING: Bristol-Myers Squibb; NHMRC grants 211086, 358395, and 1029754; NHMRC program grant 1149987; NHMRC fellowship 108026; and the Operational Infrastructure Support Program of the Victorian government of Australia.
- 11 July 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (13)
Open AccessChanges in plasma lipids predict pravastatin efficacy in secondary prevention
BACKGROUND: Statins have pleiotropic effects on lipid metabolism. The relationship between these effects and future cardiovascular events is unknown. We characterized the changes in lipids upon pravastatin treatment and defined the relationship with risk reduction for future cardiovascular events. METHODS: Plasma lipids ( n = 342) were measured in baseline and 1-year follow-up samples from a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study subcohort ( n = 4991). The associations of changes in lipids with treatment and cardiovascular outcomes were investigated using linear and Cox regression. The effect of treatment on future cardiovascular outcomes was examined by the relative risk reduction (RRR). RESULTS: Pravastatin treatment was associated with changes in 206 lipids. Species containing arachidonic acid were positively associated while phosphatidylinositol species were negatively associated with pravastatin treatment. The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C) and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4). Change in PI(36:2)/PC(38:4) mediated 58% of the treatment effect. Stratification of patients into quartiles of change in PI(36:2)/PC(38:4) indicated no benefit of pravastatin in the fourth quartile. CONCLUSION: The change in PI(36:2)/PC(38:4) predicted benefit from pravastatin, independent of change in LDL-C, demonstrating its potential as a biomarker for monitoring the clinical benefit of statin treatment in secondary prevention. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry identifier ACTRN12616000535471. FUNDING: Bristol-Myers Squibb; NHMRC grants 211086, 358395, and 1029754; NHMRC program grant 1149987; NHMRC fellowship 108026; and the Operational Infrastructure Support Program of the Victorian government of Australia.
- Open Access
- 6 September 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (17)
Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention
BACKGROUND. Plasma lipidomic measures may enable improved prediction of cardiovascular outcomes in secondary prevention. The aim of this study is to determine the association of plasma lipidomic measurements with cardiovascular events and assess their potential to predict such events. METHODS. Plasma lipids ( n = 342) were measured in a retrospective subcohort ( n = 5,991) of the LIPID study. Proportional hazards regression was used to identify lipids associated with future cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and cardiovascular death. Multivariable models adding lipid species to traditional risk factors were created using lipid ranking established from the Akaike information criterion within a 5-fold cross-validation framework. The results were tested on a diabetic case cohort from the ADVANCE study ( n = 3,779). RESULTS. Specific ceramide species, sphingolipids, phospholipids, and neutral lipids containing omega-6 fatty acids or odd-chain fatty acids were associated with future cardiovascular events (106 species) and cardiovascular death (139 species). The addition of 7 lipid species to a base model (11 conventional risk factors) resulted in an increase in the C-statistics from 0.629 (95% CI, 0.628–0.630) to 0.654 (95% CI, 0.653–0.656) for prediction of cardiovascular events and from 0.673 (95% CI, 0.671–0.675) to 0.727 (95% CI, 0.725–0.728) for prediction of cardiovascular death. Categorical net reclassification improvements for cardiovascular events and cardiovascular death were 0.083 (95% CI, 0.081–0.086) and 0.166 (95% CI, 0.162–0.170), respectively. Evaluation on the ADVANCE case cohort demonstrated significant improvement on the base models. CONCLUSIONS. The improvement in the prediction of cardiovascular outcomes, above conventional risk factors, demonstrates the potential of plasma lipidomic profiles as biomarkers for cardiovascular risk stratification in secondary prevention. FUNDING. Bristol-Myers Squibb, the National Health and Medical Research Council of Australia (grants 211086, 358395, and 1029754), and the Operational Infrastructure Support Program of the Victorian government of Australia.
- 6 September 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (17)
Open AccessLarge-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention
BACKGROUND. Plasma lipidomic measures may enable improved prediction of cardiovascular outcomes in secondary prevention. The aim of this study is to determine the association of plasma lipidomic measurements with cardiovascular events and assess their potential to predict such events. METHODS. Plasma lipids ( n = 342) were measured in a retrospective subcohort ( n = 5,991) of the LIPID study. Proportional hazards regression was used to identify lipids associated with future cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and cardiovascular death. Multivariable models adding lipid species to traditional risk factors were created using lipid ranking established from the Akaike information criterion within a 5-fold cross-validation framework. The results were tested on a diabetic case cohort from the ADVANCE study ( n = 3,779). RESULTS. Specific ceramide species, sphingolipids, phospholipids, and neutral lipids containing omega-6 fatty acids or odd-chain fatty acids were associated with future cardiovascular events (106 species) and cardiovascular death (139 species). The addition of 7 lipid species to a base model (11 conventional risk factors) resulted in an increase in the C-statistics from 0.629 (95% CI, 0.628–0.630) to 0.654 (95% CI, 0.653–0.656) for prediction of cardiovascular events and from 0.673 (95% CI, 0.671–0.675) to 0.727 (95% CI, 0.725–0.728) for prediction of cardiovascular death. Categorical net reclassification improvements for cardiovascular events and cardiovascular death were 0.083 (95% CI, 0.081–0.086) and 0.166 (95% CI, 0.162–0.170), respectively. Evaluation on the ADVANCE case cohort demonstrated significant improvement on the base models. CONCLUSIONS. The improvement in the prediction of cardiovascular outcomes, above conventional risk factors, demonstrates the potential of plasma lipidomic profiles as biomarkers for cardiovascular risk stratification in secondary prevention. FUNDING. Bristol-Myers Squibb, the National Health and Medical Research Council of Australia (grants 211086, 358395, and 1029754), and the Operational Infrastructure Support Program of the Victorian government of Australia.
- Open Access
- 3 May 2014
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 14 (1) , 1-10
A comparison of risk factors for mortality from heart failure in Asian and non-Asian populations: An overview of individual participant data from 32 prospective cohorts from the Asia-Pacific Region
Most of what is known regarding the epidemiology of mortality from heart failure (HF) comes from studies within Western populations with few data available from the Asia-Pacific region where the burden of heart failure is increasing. Individual level data from 543694 (85% Asian; 36% female) participants from 32 cohorts in the Asia Pacific Cohort Studies Collaboration were included in the analysis. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) for mortality from HF were estimated separately for Asians and non-Asians for a quintet of cardiovascular risk factors: systolic blood pressure, diabetes, body mass index, cigarette smoking and total cholesterol. All analyses were stratified by sex and study. During 3,793,229 person years of follow-up there were 614 HF deaths (80% Asian). The positive associations between elevated blood pressure, obesity, and cigarette smoking were consistent for Asians and non-Asians. There was evidence to indicate that diabetes was a weaker risk factor for death from HF for Asians compared with non-Asians: HR 1.26 (95% CI: 0.74-2.13) versus 3.04 (95% CI 1.76-5.25) respectively; p for interaction = 0.022. Additional adjustment for covariates did not materially change the overall associations. There was no good evidence to indicate that total cholesterol was a risk factor for HF mortality in either population. Most traditional cardiovascular risk factors including elevated blood pressure, obesity and cigarette smoking appear to operate similarly to increase the risk of death from HF in Asians and non-Asians populations alike.
- 3 May 2014
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 14 (1) , 1-10
Open AccessA comparison of risk factors for mortality from heart failure in Asian and non-Asian populations: An overview of individual participant data from 32 prospective cohorts from the Asia-Pacific Region
Most of what is known regarding the epidemiology of mortality from heart failure (HF) comes from studies within Western populations with few data available from the Asia-Pacific region where the burden of heart failure is increasing. Individual level data from 543694 (85% Asian; 36% female) participants from 32 cohorts in the Asia Pacific Cohort Studies Collaboration were included in the analysis. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) for mortality from HF were estimated separately for Asians and non-Asians for a quintet of cardiovascular risk factors: systolic blood pressure, diabetes, body mass index, cigarette smoking and total cholesterol. All analyses were stratified by sex and study. During 3,793,229 person years of follow-up there were 614 HF deaths (80% Asian). The positive associations between elevated blood pressure, obesity, and cigarette smoking were consistent for Asians and non-Asians. There was evidence to indicate that diabetes was a weaker risk factor for death from HF for Asians compared with non-Asians: HR 1.26 (95% CI: 0.74-2.13) versus 3.04 (95% CI 1.76-5.25) respectively; p for interaction = 0.022. Additional adjustment for covariates did not materially change the overall associations. There was no good evidence to indicate that total cholesterol was a risk factor for HF mortality in either population. Most traditional cardiovascular risk factors including elevated blood pressure, obesity and cigarette smoking appear to operate similarly to increase the risk of death from HF in Asians and non-Asians populations alike.
- Open Access
- 22 February 2011
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 32 (11) , 1416-1423
The prognostic value of adipose tissue fatty acids for incident cardiovascular disease: results from 3944 subjects in the Scottish Heart Health Extended Cohort Study
Dietary fats are routinely considered key determinants of cardiovascular risk, yet the scientific basis of this association has never been demonstrated using objective measures of fat intakes in a large prospective study in a general population. Adipose tissue was taken from 3944 participants, predominantly aged 40–59 years, in Scotland, 1984–87. Percentages of individual fatty acids were measured using gas chromatography. Over a median of 19.5 years, 870 incident cardiovascular disease (CVD) events occurred. Hazard ratios (HRs) were obtained from Cox models and the additional prognostic value, accounting for variables in the Framingham and ASSIGN CVD risk scores, were assessed using discrimination indices. Adjusting for age, sex, total and HDL-cholesterol, systolic blood pressure, smoking, hypertensive medication use, diabetes, socio-economic status and family history, the percentage of monounsaturated adipose tissue fatty acids had a positive log-linear relationship with incident CVD: the HR comparing risk between the fourth and first quartiles was 1.29 (95% confidence interval: 1.05, 1.59). n-3 polyunsaturated fat showed the reverse trend, the corresponding result being 0.77 (0.63, 0.94). These two composite variables improved the classification of incident CVD events by 1.0 and 6.4%, respectively, with only the latter being significant at the 5% level. A diet which is proportionately rich in polyunsaturated fat, as opposed to other fats, is expected to decrease the risk of CVD independently of the effects of common CVD risk factors, including social deprivation. Taking account of such diets improves the classification of future CVD events.
- 22 February 2011
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 32 (11) , 1416-1423
Open AccessThe prognostic value of adipose tissue fatty acids for incident cardiovascular disease: results from 3944 subjects in the Scottish Heart Health Extended Cohort Study
Dietary fats are routinely considered key determinants of cardiovascular risk, yet the scientific basis of this association has never been demonstrated using objective measures of fat intakes in a large prospective study in a general population. Adipose tissue was taken from 3944 participants, predominantly aged 40–59 years, in Scotland, 1984–87. Percentages of individual fatty acids were measured using gas chromatography. Over a median of 19.5 years, 870 incident cardiovascular disease (CVD) events occurred. Hazard ratios (HRs) were obtained from Cox models and the additional prognostic value, accounting for variables in the Framingham and ASSIGN CVD risk scores, were assessed using discrimination indices. Adjusting for age, sex, total and HDL-cholesterol, systolic blood pressure, smoking, hypertensive medication use, diabetes, socio-economic status and family history, the percentage of monounsaturated adipose tissue fatty acids had a positive log-linear relationship with incident CVD: the HR comparing risk between the fourth and first quartiles was 1.29 (95% confidence interval: 1.05, 1.59). n-3 polyunsaturated fat showed the reverse trend, the corresponding result being 0.77 (0.63, 0.94). These two composite variables improved the classification of incident CVD events by 1.0 and 6.4%, respectively, with only the latter being significant at the 5% level. A diet which is proportionately rich in polyunsaturated fat, as opposed to other fats, is expected to decrease the risk of CVD independently of the effects of common CVD risk factors, including social deprivation. Taking account of such diets improves the classification of future CVD events.
- Open Access
- 1 January 2010
- Published by Wiley in Journal of the International AIDS Society
- Vol. 13 (1) , 12
Elevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: a cross‐sectional study
Patients infected with HIV have an increased risk for accelerated atherosclerosis. Elevated levels of osteoprotegerin, an inflammatory cytokine receptor, have been associated with a high incidence of cardiovascular disease (including peripheral arterial disease, or PAD), acute coronary syndrome, and cardiovascular mortality. The objective of this study was to determine whether PAD is prevalent in an HIV-infected population, and to identify an association with HIV-specific and traditional cardiovascular risk factors, as well as levels of osteoprotegerin.
- 1 January 2010
- Published by Wiley in Journal of the International AIDS Society
- Vol. 13 (1) , 12
Open AccessElevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: a cross‐sectional study
Patients infected with HIV have an increased risk for accelerated atherosclerosis. Elevated levels of osteoprotegerin, an inflammatory cytokine receptor, have been associated with a high incidence of cardiovascular disease (including peripheral arterial disease, or PAD), acute coronary syndrome, and cardiovascular mortality. The objective of this study was to determine whether PAD is prevalent in an HIV-infected population, and to identify an association with HIV-specific and traditional cardiovascular risk factors, as well as levels of osteoprotegerin.
- 1 January 2010
- Published by Springer Nature
- p. 425-436
Individual Disability-Adjusted Life Year: A Summary Health Outcome Indicator Used for Prospective Studies
- 1 January 2010
- Published by Springer Nature
- p. 425-436
Individual Disability-Adjusted Life Year: A Summary Health Outcome Indicator Used for Prospective Studies
- Open Access
- 3 April 2009
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 6 (4) , 1358-1370
Smoking and the Risk of Upper Aero Digestive Tract Cancers for Men and Women in the Asia-Pacific Region
Although smoking is an established causal factor for upper aero digestive tract cancer (UADTC), most of the evidence originates from the West. Thus, we analysed data from 455,409 subjects in the Asia Pacific Cohort Studies Collaboration. Over a median of around six years follow-up, 371 deaths from UADTC were observed. The hazard ratio (95% confidence interval) for current smokers, compared with those who had never smoked, was 2.36 (1.76 – 3.16), adjusted for age and alcohol drinking. Tobacco control policies are urgently required in Asia to prevent millions of deaths from UADTC that smoking will otherwise cause.
- 3 April 2009
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 6 (4) , 1358-1370
Open AccessSmoking and the Risk of Upper Aero Digestive Tract Cancers for Men and Women in the Asia-Pacific Region
Although smoking is an established causal factor for upper aero digestive tract cancer (UADTC), most of the evidence originates from the West. Thus, we analysed data from 455,409 subjects in the Asia Pacific Cohort Studies Collaboration. Over a median of around six years follow-up, 371 deaths from UADTC were observed. The hazard ratio (95% confidence interval) for current smokers, compared with those who had never smoked, was 2.36 (1.76 – 3.16), adjusted for age and alcohol drinking. Tobacco control policies are urgently required in Asia to prevent millions of deaths from UADTC that smoking will otherwise cause.
- 1 April 2009
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 16 (2) , 210-214
The metabolic syndrome is not a sensible tool for predicting the risk of coronary heart disease
Background The metabolic syndrome (MS) is a popularly used risk marker for coronary heart disease (CHD), yet its utility is in doubt. Design Cohort study based ...
- 1 April 2009
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 16 (2) , 210-214
The metabolic syndrome is not a sensible tool for predicting the risk of coronary heart disease
Background The metabolic syndrome (MS) is a popularly used risk marker for coronary heart disease (CHD), yet its utility is in doubt. Design Cohort study based ...
- Open Access
- 1 January 2009
- Published by SAGE Publications in Women's Health
- Vol. 5 (1) , 69-77
Migraine and the Risk of Coronary Heart Disease and Ischemic Stroke in Women
Migraine is a common chronic disorder, especially amongst women – approximately 18% of US women will have had a migraine attack within the past year. Cardiovascular disease is the biggest killer in the same population. This review summarizes the best available epidemiological evidence for an independent association between migraine and cardiovascular disease amongst women. The most reliable evidence comes from the Women's Health Study, which found that migraine with aura raised the risk of ischemic stroke by 91% (95% CI: 17–210%) and myocardial infaction by 108% (95% CI: 30–231%). Migraine without aura raised both risks by approximately 25%. The other prospective studies that were identified gave broadly supportive results, and suggested that the risks from migraine were attenuated with age. It would be prudent for women who suffer migraine with aura to seek medical advice and consider lifestyle changes in order to improve their cardiovascular risk profile.
- 1 January 2009
- Published by SAGE Publications in Women's Health
- Vol. 5 (1) , 69-77
Open AccessMigraine and the Risk of Coronary Heart Disease and Ischemic Stroke in Women
Migraine is a common chronic disorder, especially amongst women – approximately 18% of US women will have had a migraine attack within the past year. Cardiovascular disease is the biggest killer in the same population. This review summarizes the best available epidemiological evidence for an independent association between migraine and cardiovascular disease amongst women. The most reliable evidence comes from the Women's Health Study, which found that migraine with aura raised the risk of ischemic stroke by 91% (95% CI: 17–210%) and myocardial infaction by 108% (95% CI: 30–231%). Migraine without aura raised both risks by approximately 25%. The other prospective studies that were identified gave broadly supportive results, and suggested that the risks from migraine were attenuated with age. It would be prudent for women who suffer migraine with aura to seek medical advice and consider lifestyle changes in order to improve their cardiovascular risk profile.
- Open Access
- 1 November 2008
- Published by SAGE Publications in Women's Health
- Vol. 4 (6) , 561-564
Cardiovascular Risk in Women with Nonspecific Chest Pain
Evaluation of: Robinson JG, Wallace R, Limacher M et al.: Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative hormone trials). Am. J. Cardiol. 102(6), 693–699 (2008). Chest pain is common, and often a specific cause fails to be diagnosed. There is particular concern that many women with a diagnosis of nonspecific chest pain (NSCP) may have atypical indications of coronary artery disease. Analysis of data from the Women's Health Initiative hormone therapy trials, amongst 24,834 postmenopausal women aged 50–79 years who were initially free of cardiovascular disease, found that NSCP was associated with a 139% (95% CI: 46–292%) increase in the risk of subsequent angina. Similar proportional increases in risk were found for cardiac surgery or interventions and nonfatal myocardial infarction. Thus, a diagnosis of NSCP in a woman, using current technology, does not rule out the possibility of increased coronary risk. It would be prudent to treat women with NSCP as being at a higher than average risk of cardiovascular disease
- 1 November 2008
- Published by SAGE Publications in Women's Health
- Vol. 4 (6) , 561-564
Open AccessCardiovascular Risk in Women with Nonspecific Chest Pain
Evaluation of: Robinson JG, Wallace R, Limacher M et al.: Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative hormone trials). Am. J. Cardiol. 102(6), 693–699 (2008). Chest pain is common, and often a specific cause fails to be diagnosed. There is particular concern that many women with a diagnosis of nonspecific chest pain (NSCP) may have atypical indications of coronary artery disease. Analysis of data from the Women's Health Initiative hormone therapy trials, amongst 24,834 postmenopausal women aged 50–79 years who were initially free of cardiovascular disease, found that NSCP was associated with a 139% (95% CI: 46–292%) increase in the risk of subsequent angina. Similar proportional increases in risk were found for cardiac surgery or interventions and nonfatal myocardial infarction. Thus, a diagnosis of NSCP in a woman, using current technology, does not rule out the possibility of increased coronary risk. It would be prudent to treat women with NSCP as being at a higher than average risk of cardiovascular disease